Susquehanna International Group
LXEO icon

Susquehanna International Group’s Lexeo Therapeutics LXEO Stock Holding History

Susquehanna International Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270K Buy
46,998
+9,989
+27% +$70.8K ﹤0.01% 11112
2025
Q4 		$367K Buy
37,009
+8,078
+28% +$73.7K ﹤0.01% 9479
2025
Q3 		$192K Sell
28,931
-19,080
-40% -$92.3K ﹤0.01% 11039
2025
Q2 		$193K Sell
48,011
-2,136
-4% -$7.02K ﹤0.01% 11248
2025
Q1 		$174K Buy
50,147
+38,999
+350% +$173K ﹤0.01% 11086
2024
Q4 		$73.4K Buy
+11,148
New +$87.8K ﹤0.01% 11514
2024
Q2 		– Sell
-12,041
Closed -$189K – 12877
2024
Q1 		$189K Buy
+12,041
New +$188K ﹤0.01% 10657

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return